Myelodysplastic Syndrome (MDS) Clinical Trials

9 recruiting

Myelodysplastic Syndrome (MDS) Trials at a Glance

9 actively recruiting trials for myelodysplastic syndrome (mds) are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 1 with 6 trials, with the heaviest enrollment activity in New York, Bethesda, and Cincinnati. Lead sponsors running myelodysplastic syndrome (mds) studies include National Heart, Lung, and Blood Institute (NHLBI), Children's Hospital Medical Center, Cincinnati, and Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

Browse myelodysplastic syndrome (mds) trials by phase

Treatments under study

About Myelodysplastic Syndrome (MDS) Clinical Trials

Looking for clinical trials for Myelodysplastic Syndrome (MDS)? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myelodysplastic Syndrome (MDS) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myelodysplastic Syndrome (MDS) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 2

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

Severe Aplastic Anemia (SAA)Hypo-Plastic Myelodysplastic Syndrome (MDS)
National Heart, Lung, and Blood Institute (NHLBI)56 enrolled1 locationNCT03520647
Recruiting
Phase 1Phase 2

Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS

Proton TherapyAcute Myeloid Leukemia (AML)Myelodysplastic Neoplasm+2 more
Institute of Hematology and Blood Transfusion, Czech Republic16 enrolled2 locationsNCT07532824
Recruiting
Phase 1Phase 2

Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

Myelodysplastic Syndrome (MDS)Severe Aplastic AnemiaHypo-Plastic MDS
National Heart, Lung, and Blood Institute (NHLBI)37 enrolled1 locationNCT03173937
Recruiting
Phase 1

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS)Relapsed/Refractory Acute Myeloid Leukemia (AML)
Cullinan Therapeutics Inc.60 enrolled11 locationsNCT05143996
Recruiting
Phase 1

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

Myelodysplastic Syndrome (MDS)Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Acute Myeloid Leukaemia (AML)
medac GmbH36 enrolled4 locationsNCT05534620
Recruiting

Patient Reported Outcomes and Patient Voice Among Patients Diagnosed With Low Risk Myelodysplastic Syndrome (LR-MDS) or Unexplained Anemia In Japan

Myelodysplastic Syndrome (MDS)
Bristol-Myers Squibb50 enrolled1 locationNCT07008820
Recruiting
Phase 1

A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)
Taiho Pharmaceutical Co., Ltd.40 enrolled10 locationsNCT04608110
Recruiting
Phase 2

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Fanconi AnemiaSevere Marrow FailureMyelodysplastic Syndrome (MDS)+1 more
Children's Hospital Medical Center, Cincinnati70 enrolled3 locationsNCT02143830
Recruiting
Phase 1

A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.100 enrolled7 locationsNCT06550713